| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Joseph Truitt is Director at LRMR. Joseph Truitt's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $7K at current prices.
Net of sales, the LRMR filings show accumulation of 2,750 shares.
Joseph Truitt has 9 Form 4 filings on record from September 2020 to September 2026, across 2 companies: Director at Century Therapeutics (IPSC), 2026; Director at Larimar Therapeutics (LRMR), 2020–2026.
The 9 reported transactions were 8 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $10K and no sales.
The only open-market purchase was 2,750 shares of LRMR at an average $3.73 on May 17, 2023, about $10K. Twelve months later LRMR was up 101%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 17, 2023 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 2,750 | $3.73 | $10,257.50 | New | +13.3% | +101.4% |